Proequities, Inc.
- SEC CIK
- 0000752798
- Latest filing
- Aug 12, 2025
ALNY holding history
Alnylam Pharmaceuticals, Inc. in every 13F filed by Proequities, Inc., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ALNY overviewAll 13F holders of ALNYFull Q2 2025 holdings
- Shares (Q1 2025)
- 0
- Sold out in Q1 2025
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 11
- Since Q1 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q1 2025 | 0 | $0 | 0.0% | −5−100.0% | Sold out | Holders |
| Q4 2024 | 5 | $1.33K | <0.1% | +2+66.7% | Added | Holders |
| Q3 2024 | 3 | $825 | <0.1% | −19−86.4% | Reduced | Holders |
| Q2 2024 | 22 | $5.35K | <0.1% | +1+4.8% | Added | Holders |
| Q1 2024 | 21 | $3.14K | <0.1% | −5−19.2% | Reduced | Holders |
| Q4 2023 | 26 | $4.98K | <0.1% | +23+766.7% | Added | Holders |
| Q3 2023 | 3 | $531 | <0.1% | +3 | New | Holders |
| Q2 2022 | 0 | $0 | 0.0% | −76−100.0% | Sold out | Holders |
| Q1 2022 | 76 | $12.0K | <0.1% | +4+5.6% | Added | Holders |
| Q4 2021 | 72 | $12.0K | <0.1% | +30+71.4% | Added | Holders |
| Q3 2021 | 42 | $8.00K | <0.1% | −3−6.7% | Reduced | Holders |
| Q2 2021 | 45 | $8.00K | <0.1% | +2+4.7% | Added | Holders |
| Q1 2021 | 43 | $6.00K | <0.1% | – | – | Holders |
Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.